polymeras
rna
virus
lack
proofread
capac
found
polymeras
dna
virus
lead
high
error
rate
low
replic
fidel
although
high
mutat
rate
rna
virus
enabl
readili
adapt
environment
chang
also
risk
lethal
mutagenesi
accumul
mutat
corrupt
essenti
function
smith
et
al
reveal
case
sever
acut
respiratori
syndrom
coronaviru
sarscov
exoribonucleas
domain
exon
nonstructur
protein
provid
proofread
activ
protect
viru
mutagenesi
previou
work
coronavirus
largest
rna
virus
shown
exon
delet
lead
reduc
replic
fidel
attenu
virul
thu
smith
et
al
specul
exon
proofread
enzym
test
hypothesi
infect
cell
wildtyp
exon
exondelet
sarscov
presenc
mutagen
pyrimidin
analogu
inde
loss
exon
sensit
viru
shown
reduct
viral
replic
sarscov
compar
exon
sarscov
furthermor
genom
sequenc
viral
popul
treatment
reveal
sarscov
harbour
mutat
wherea
exon
sarscov
accumul
mutat
mutat
utoc
atog
transit
respect
characterist
nucleotid
mismatch
caus
incorpor
metabolit
taken
togeth
result
show
exon
proofread
protect
sarscov
deleteri
effect
mutagen
exon
proofread
protect
sarscov
deleteri
effect
mutagen
date
antivir
treatment
exist
coronavirus
neither
ribavirin
two
broadli
act
antivir
avail
clinic
today
consist
antivir
effect
sarscov
howev
ribavirin
mutagen
nucleosid
analogu
might
similar
effect
absenc
exon
consist
murin
cov
sensit
ribavirin
exon
murin
cov
although
experi
indic
mechan
besid
mutagenesi
exampl
reduc
rna
synthesi
contribut
exondepend
effect
cell
use
sarscov
infect
fail
take
ribavirin
sensit
sarscov
ribavirin
remain
unclear
nevertheless
coronaviru
exon
first
proofread
protein
report
rna
viru
target
exon
promis
strategi
develop
new
coronaviru
inhibitor
sensit
exist
antivir
